{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Na TU"],"pubmed_abstract":["A chemodiverse library of new semi-synthetic antimicrobial peptides is reported herein. The polymyxin B nonapeptide (PMBN) holds promise as a developmental platform to access potent antimicrobial lipopeptide derivatives that circumvent the serious side effects of natural polymyxins used in clinical settings. By combining our unique radical thiol-ene lipidation strategy (CLipPA) with a chemoenzymatic synthesis, we achieved the chemoselective re-functionalisation of semi-synthetic PMBN, affording a family of potent \"soft drugs\" decorated with linear, cyclo- and branched alkyl and aromatic esters of varying steric properties. The high efficiency of this late-stage diversification strategy is demonstrated for lipopeptide semi-synthesis. In this process, the significance of the lipid orientatio"],"journal":["RSC medicinal chemistry"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12907753"],"repository":["biostudies-literature"],"pubmed_title":["Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens."],"pmcid":["PMC12907753"],"pubmed_authors":["Siow A","Goggin BL","Allison JR","Sander V","Cook GM","Daysh Z","Ferguson SA","Brimble MA","Owen JG","Painter GF","Campbell G","Hanna CC","Na TU","Hermant YO","Harris PWR","Cameron AJ","Chan STS","Davidson AJ"],"additional_accession":[]},"is_claimable":false,"name":"Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens.","description":"A chemodiverse library of new semi-synthetic antimicrobial peptides is reported herein. The polymyxin B nonapeptide (PMBN) holds promise as a developmental platform to access potent antimicrobial lipopeptide derivatives that circumvent the serious side effects of natural polymyxins used in clinical settings. By combining our unique radical thiol-ene lipidation strategy (CLipPA) with a chemoenzymatic synthesis, we achieved the chemoselective re-functionalisation of semi-synthetic PMBN, affording a family of potent \"soft drugs\" decorated with linear, cyclo- and branched alkyl and aromatic esters of varying steric properties. The high efficiency of this late-stage diversification strategy is demonstrated for lipopeptide semi-synthesis. In this process, the significance of the lipid orientatio","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T05:05:21.48Z","creation":"2026-07-09T10:38:05.67Z"},"accession":"S-EPMC12907753","cross_references":{"pubmed":["41705127"],"doi":["10.1039/d5md01141h"]}}